GenScript ProBio as well AbTis enter into an Exclusive Worldwide License Agreement for ADC Targeting

 
PISCATAWAY, N.J. - June 22, 2022 - PRLog -- On the 8th of December 2021, GenScript ProBio entered into a collaboration with AbTis, a Korean biotechnology firm devoted to the research and development of antibody-drug conjugate ("ADC") to give AbTis the exclusive global license for GenScript ProBio's anti-Claudin 18.2 monoclonal antigens ("Licensed Antibody"), to commercialize and develop the ADC. AbTis and GenScript ProBio will enter into an exclusive CDMO collaboration to support the preclinical CMC development as well as commercial and clinical manufacturing of the antibodies for the ADC product.

GenScript ProBio is based on the 17-year GenScript R&D and manufacturing expertise and its well-integrated platforms and strong capabilities on the platform have provided the discovery process and anti-protein CDMO services to clients across the world. Additionally, GenScript ProBio has also formed partnerships with three transgenic animal platforms both in the US and overseas, which allows single-stop discovery services for human antibodies using the platform's animals.

Dr. Sang Jeon Chung, CEO of AbTis stated, "We are pleased to join forces with GenScript ProBio which is a highly specific CDMO company with deep knowledge and vast knowledge of antibody discovery. We are looking eagerly to work alongside GenScript ProBio to help us create new and exciting anti-drug conjugates to patient benefit and we'll work together to accelerate the process of transformation in pharmaceuticals and help shape the future."

Claudin18.2 is currently among the top well-known areas of pharmaceutical research, particularly those working with ADC development. GenScript ProBio team has completed antibody discovery, functional validation, and development of stable cell line (https://www.genscriptprobio.com/add-overexpression-cell-l...) for this Licensed Antibody. This continues to create and market ADC products that are based on this Licensed Antibody.

"We are thrilled to collaborate with AbTis and we are honoured to be able to help this exciting antibody-drug conjugate research project," said Dr. Brian Min, CEO of GenScript ProBio. "I believe that this partnership will further demonstrate the advantages of technology and platform for both sides. We look at using GenScript ProBio's extensive CMC development expertise to bring the project on the road to IND and commercialization for the benefit of patients shortly."

About GenScript ProBio

GenScript ProBio is the  Antibody CDMO (https://www.genscriptprobio.com/) segment of GenScript Biotech, proactively providing end-to-end service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in antibody-drug and cell and gene therapy to accelerate drug development for customers.

Toward the mission of "Innovation through Collaboration", GenScript ProBio is committed to helping customers shorten the timeline for the development of biological drugs from discovery to commercialization, significantly lowering R&D costs and building a healthier future.

More information: https://www.genscriptprobio.com

Contact
Genscript Probio
***@gmail.com
End
Source: » Follow
Email:***@gmail.com
Tags:Antibody CDMO
Industry:Biotech
Location:Piscataway - New Jersey - United States
Subject:Projects
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share